Suggestions

Du même auteur

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Archive ouverte | Houot, Roch | CCSD

International audience. Lenalidomide is a potent immunomodulatory agent that has demonstrated clinical activity in the treatment of both diffuse large B cell lymphomas (DLBCL) and mantle cell lymphomas (MCL). In rel...

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study

Archive ouverte | Morschhauser, Franck | CCSD

International audience. CONTEXTE:Lenalidomide plus rituximab est approuvé pour traiter les patients atteints de lymphome folliculaire en rechute ou réfractaire. Il a été démontré que l'obinutuzumab améliore la cytot...

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Archive ouverte | Bachy, Emmanuel | CCSD

International audience. Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report effica...

Chargement des enrichissements...